Depleting CD8+ T cells significantly abrogated the anti-tumor effect of both chemo-immunotherapy combinations (5-FU+ICB: p < 0.0001; cisplatin+ICB: p = 0.026) (Figures 3E, F). Here, CD8A is linked to neoplasm.